Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04802083 Available - Covid19 Clinical Trials

COVID-19 Soliris Expanded Access Protocol

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides participants with COVID-19 access to Soliris.

NCT ID: NCT04657458 Available - Covid19 Clinical Trials

Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS

Start date: n/a
Phase:
Study type: Expanded Access

Infusion Treatment Using Bone Marrow Mesenchymal Stem Cell (bmMSC) Derived Extracellular Vesicle Product, ExoFlo™, for COVID-19 Associated ARDS (EXIT COVID-19), is currently being studied in Protocol DB-EF-PhaseII-001 in patients with COVID-19 associated moderate to severe Acute Respiratory Distress Syndrome (ARDS). This expanded access protocol is an open-label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase II randomized controlled trial because they: - Do not meet phase II eligibility criteria at current phase II sites. - Do meet phase II eligibility criteria but cannot access phase II sites. - Do not meet phase II eligibility criteria & cannot access phase II sites. •

NCT ID: NCT04657406 Available - Covid19 Clinical Trials

Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will provide access to the investigational product ZofinTM (OrganicellTM Flow) for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

NCT ID: NCT04646031 Available - Covid19 Clinical Trials

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening condition.

NCT ID: NCT04636554 Available - Covid19 Clinical Trials

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Start date: n/a
Phase:
Study type: Expanded Access

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

NCT ID: NCT04617535 Available - Covid19 Clinical Trials

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

Provide Compassionate Use access to REGN-COV2 for adult patients with recently diagnosed mild-to-moderate coronavirus disease (COVID-19) who are at high risk for poor outcomes.

NCT ID: NCT04597242 Available - Covid19 Clinical Trials

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI), including right-sided endocarditis (R-IE), who are hospitalized with coronavirus disease 2019 (COVID-19). Patients with left-sided endocarditis (L-IE) are excluded. Patients will receive a single dose of exebacase. Patients will continue to receive antistaphylococcal antibiotics as prescribed by the treating physician. Exebacase Phase 3 study sites (Study CF-301-105) may participate in this Expanded Access study (Study CF-301-107). Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to standard-of-care antibiotics to treat S. aureus BSI including IE.